

Forest plots for review question: What are the relative benefits and harms of further-line psychological, psychosocial, pharmacological and physical interventions (alone or in combination), for adults with depression showing an

inadequate response to at least one previous intervention for the current episode?

Comparison 1. Augmenting with cognitive and cognitive behavioural therapies versus continuing with antidepressant (+/ waitlist or attention-placebo)

Figure 2: Depression symptomatology endpoint






Figure 3: Depression symptomatology change score**Figure 4: Depression symptomatology at 2-3 month follow-up**




Figure 5: Depression symptomatology at 4-6 month follow-up**Figure 6: Depression symptomatology at 11-12 month follow-up****Figure 7: Depression symptomatology at 40-month follow-up**

Figure 8: Remission (ITT)




Figure 9: Remission (ITT) at 3-month follow-up







Figure 10: Remission (ITT) at 6-month follow-up

Test for subgroup differences: Not applicable
AD: antidepressant

Figure 11: Remission (ITT) at 12-month follow-up

Test for subgroup differences: Not applicable
AD: antidepressant

Figure 12: Remission (ITT) at 40-month follow-up

Test for subgroup differences: Not applicable
AD: antidepressant

Figure 13: Response (ITT)




Figure 14: Response (ITT) at 3-month follow-up







Figure 15: Response (ITT) at 6-month follow-up**Figure 16: Response (ITT) at 12-month follow-up****Figure 17: Response (ITT) at 40-month follow-up**


Figure 18: Discontinuation due to any reason

Figure 19: Discontinuation due to side effects




Figure 20: Quality of life endpoint




Figure 21: Quality of life physical component score (PCS) endpoint




Figure 22: Quality of life mental component score (MCS) endpoint




Figure 23: Quality of life physical component score (PCS) at 3-month follow-up




Figure 24: Quality of life mental component score (MCS) at 3-month follow-up










Figure 25: Quality of life physical component score (PCS) at 6-month follow-up**Figure 26: Quality of life mental component score (MCS) at 6-month follow-up****Figure 27: Quality of life physical component score (PCS) at 12-month follow-up****Figure 28: Quality of life mental component score (MCS) at 12-month follow-up**

Figure 29: Quality of life physical component score (PCS) at 40-month follow-up




Test for subgroup differences: Not applicable
AD: antidepressant

Figure 30: Quality of life mental component score (MCS) at 40-month follow-up




Test for subgroup differences: Not applicable
AD: antidepressant

Figure 31: Functional impairment endpoint



AD: antidepressant

Figure 32: Functional impairment at 11-month follow-up



Test for subgroup differences: Not applicable
AD: antidepressant

Comparison 2. Augmenting with cognitive and cognitive behavioural therapies versus augmenting with counselling

Figure 33: Depression symptomatology endpoint




Figure 34: Remission (ITT)




Figure 35: Discontinuation due to any reason




Figure 36: Discontinuation due to side effects





Figure 37: Functional impairment endpoint



Comparison 3. Augmenting with counselling versus continuing with antidepressant

Figure 38: Depression symptomatology endpoint




Figure 39: Remission (ITT)




Figure 40: Discontinuation due to any reason







Figure 41: Discontinuation due to side effects

Test for subgroup differences: Not applicable
AD: antidepressant

Figure 42: Functional impairment endpoint

Test for subgroup differences: Not applicable
AD: antidepressant

Comparison 4. Augmenting with IPT versus continuing with antidepressant

Figure 43: Depression symptomatology endpoint

AD: antidepressant

Figure 44: Depression symptomatology change score




Figure 45: Depression symptomatology at 1-3 month follow-up




Figure 46: Depression symptomatology at 12-month follow-up





Figure 47: Remission (ITT)

Figure 48: Response (ITT)




Figure 49: Discontinuation due to any reason




Figure 50: Global functioning endpoint




Figure 51: Global functioning at 3-month follow-up





Figure 52: Global functioning at 12-month follow-up



Comparison 5. Augmenting with short-term psychodynamic psychotherapy versus continuing with antidepressant

Figure 53: Depression symptomatology endpoint






Figure 54: Depression symptomatology change score




Test for subgroup differences: Not applicable
AD: antidepressant

Figure 55: Depression symptomatology at 3-month follow-up




Test for subgroup differences: Not applicable
AD: antidepressant

Figure 56: Depression symptomatology at 6-month follow-up



Test for subgroup differences: Not applicable
AD: antidepressant

Figure 57: Depression symptomatology at 12-month follow-up



Test for subgroup differences: Not applicable
AD: antidepressant

Figure 58: Remission (ITT)




Figure 59: Remission (ITT) at 12-month follow-up




Figure 60: Response (ITT) at 12-month follow-up






Figure 61: Discontinuation due to any reason



AD: antidepressant


Comparison 6. Augmenting with long-term psychodynamic psychotherapy versus continuing with antidepressant

Figure 62: Depression symptomatology endpoint




Test for subgroup differences: Not applicable
AD: antidepressant

Figure 63: Depression symptomatology at 6-month follow-up



Test for subgroup differences: Not applicable
AD: antidepressant

Figure 64: Depression symptomatology at 1-year follow-up



Test for subgroup differences: Not applicable
AD: antidepressant

Figure 65: Depression symptomatology at 2-year follow-up




Figure 66: Remission (ITT)




Figure 67: Remission (ITT) at 2-year follow-up





Figure 68: Discontinuation due to any reason



Comparison 7. Augmenting with self-help versus continuing with the antidepressant (+/- attention-placebo)

Figure 69: Depression symptomatology endpoint




Figure 70: Depression symptomatology change score




Figure 71: Depression symptomatology at 1-month follow-up





Figure 72: Discontinuation due to any reason



Comparison 8. Augmenting with self-help and switching to SSRI versus switching to SSRI-only

Figure 73: Depression symptomatology endpoint




Figure 74: Depression symptomatology change score




Figure 75: Remission (ITT)




Figure 76: Response (ITT)





Figure 77: Discontinuation due to any reason



Comparison 9. Augmenting with art therapy versus attention-placebo

Figure 78: Depression symptomatology endpoint




Figure 79: Depression symptomatology change score





Figure 80: Discontinuation due to any reason



Comparison 10. Augmenting with eye movement desensitization reprocessing (EMDR) versus augmenting with cognitive behavioural therapy

Figure 81: Depression symptomatology endpoint




Figure 82: Remission (ITT)




Figure 83: Remission (ITT) at 6-month follow-up








Figure 84: Discontinuation due to any reason**Figure 85: Global functioning at endpoint****Figure 86: Global functioning at 6-month follow-up****Comparison 11. Increasing the dose of SSRI versus continuing SSRI at the same dose****Figure 87: Depression symptomatology endpoint**

Figure 88: Depression symptomatology change score




Figure 89: Remission (ITT)




Figure 90: Response (ITT)




Figure 91: Discontinuation due to any reason




Figure 92: Discontinuation due to side effects




Figure 93: Quality of life physical component score (PCS) endpoint





Figure 94: Quality of life mental component score (MCS) endpoint



Comparison 12. Increasing the dose of SSRI versus switching to SNRI

Figure 95: Depression symptomatology endpoint




Figure 96: Depression symptomatology change score




Figure 97: Remission (ITT)




Figure 98: Response (ITT)




Figure 99: Discontinuation due to any reason




Figure 100: Discontinuation due to side effects





Figure 101: Quality of life endpoint



Comparison 13. Increasing the dose of SSRI versus augmenting with TCA

Figure 102: Depression symptomatology endpoint




Figure 103: Depression symptomatology change score




Figure 104: Remission (ITT)




Figure 105: Discontinuation due to any reason





Figure 106: Discontinuation due to side effects



Comparison 14. Increasing the dose of SSRI versus augmenting with antipsychotic

Figure 107: Depression symptomatology endpoint




Figure 108: Depression symptomatology change score




Figure 109: Remission (ITT)




Figure 110: Response (ITT)




Figure 111: Discontinuation due to any reason




Figure 112: Discontinuation due to side effects




Figure 113: Functional remission (GAF score ≥71)





Figure 114: Global functioning endpoint



Comparison 15. Increasing the dose of SSRI versus augmenting with lithium

Figure 115: Depression symptomatology endpoint




Figure 116: Depression symptomatology change score




Figure 117: Remission (ITT)




Figure 118: Discontinuation due to any reason





Figure 119: Discontinuation due to side effects



Comparison 16. Switching to SSRI versus continuing with antidepressant

Figure 120: Depression symptomatology change score




Figure 121: Remission (ITT)






Figure 122: Response (ITT)



AD: antidepressant

Figure 123: Discontinuation due to any reason



AD: antidepressant




Figure 124: Discontinuation due to side effects**Comparison 17. Switching to a different SSRI versus continuing same SSRI****Figure 125: Remission (ITT)****Figure 126: Response (ITT)**




Figure 127: Discontinuation due to any reason**Figure 128: Discontinuation due to side effects****Comparison 18. Switching to SSRI versus antipsychotic****Figure 129: Depression symptomatology change score**

Figure 130: Remission (ITT)




Figure 131: Response (ITT)




Figure 132: Discontinuation due to any reason





Figure 133: Discontinuation due to side effects

Comparison 19. Switching to combined SSRI + antipsychotic versus switching to antipsychotic-only


Figure 134: Depression symptomatology change score



Figure 135: Remission (ITT)**Figure 136: Response (ITT)**

Figure 137: Discontinuation due to any reason





Figure 138: Discontinuation due to side effects



Comparison 20. Augmenting with SSRI versus augmenting with lithium

Figure 139: Depression symptomatology change score









Figure 140: Remission (ITT)**Comparison 21. Switching to TCA versus SSRI****Figure 141: Depression symptomatology endpoint****Figure 142: Remission (ITT)****Figure 143: Response (ITT)**

Figure 144: Discontinuation due to any reason



Comparison 22. Switching to TCA versus augmenting with mirtazapine

Figure 145: Depression symptomatology endpoint




Figure 146: Depression symptomatology change score




Figure 147: Remission (ITT)





Figure 148: Discontinuation due to any reason



Comparison 23. Switching to mianserin versus continuing with antidepressant

Figure 149: Depression symptomatology change score




Figure 150: Remission (ITT)




Figure 151: Response (ITT)






Figure 152: Discontinuation due to any reason



Test for subgroup differences: Not applicable
AD: antidepressant


Figure 153: Discontinuation due to side effects



Test for subgroup differences: Not applicable
AD: antidepressant

Comparison 24. Augmenting with mianserin versus continuing with antidepressant (+/- placebo)

Figure 154: Depression symptomatology change score



Test for subgroup differences: Not applicable
AD: antidepressant



Figure 155: Remission (ITT)**Figure 156: Response (ITT)**

Figure 157: Discontinuation due to any reason





Figure 158: Discontinuation due to side effects



Comparison 25. Augmenting with mianserin versus increasing dose of antidepressant

Figure 159: Remission (ITT)




Figure 160: Response (ITT)





Figure 161: Discontinuation due to any reason



Comparison 26. Augmenting with mianserin versus switch to mianserin

Figure 162: Depression symptomatology change score




Figure 163: Remission (ITT)




Figure 164: Response (ITT)




Figure 165: Discontinuation due to any reason





Figure 166: Discontinuation due to side effects



Comparison 27. Increasing the dose of SNRI versus continuing SNRI at the same dose

Figure 167: Depression symptomatology change score




Figure 168: Remission (ITT)




Figure 169: Response (ITT)




Figure 170: Discontinuation due to any reason





Figure 171: Discontinuation due to side effects








Comparison 28. Switching to SNRI versus continuing with antidepressant**Figure 172: Remission (ITT)****Figure 173: Response (ITT)****Figure 174: Discontinuation due to any reason**

Figure 175: Discontinuation due to side effects




Test for subgroup differences: Not applicable
AD: antidepressant

Figure 176: Quality of life physical component score (PCS) change score



Test for subgroup differences: Not applicable
AD: antidepressant

Figure 177: Quality of life mental component score (MCS) change score



Test for subgroup differences: Not applicable
AD: antidepressant

Comparison 29. Switching to SNRI versus switching to another antidepressant from same class

Figure 178: Depression symptomatology change score




Figure 179: Remission (ITT)







Figure 180: Response (ITT)**Figure 181: Discontinuation due to any reason**

Figure 182: Discontinuation due to side effects



Comparison 30. Switching to SNRI versus switching to bupropion

Figure 183: Depression symptomatology change score




Figure 184: Remission (ITT)












Figure 185: Response (ITT)**Figure 186: Discontinuation due to side effects****Comparison 31. Switching to SNRI versus switching to mirtazapine****Figure 187: Remission (ITT)****Figure 188: Response (ITT)**

Figure 189: Discontinuation due to any reason**Figure 190: Discontinuation due to side effects****Figure 191: Quality of life physical component score (PCS) change score****Figure 192: Quality of life mental component score (MCS) change score**

Comparison 32. Switching to bupropion versus placebo

Figure 193: Depression symptomatology change score




Figure 194: Remission (ITT)




Figure 195: Response (ITT)




Figure 196: Discontinuation due to any reason





Figure 197: Discontinuation due to side effects



Comparison 33. Switching to bupropion versus switching to another antidepressant from same class

Figure 198: Depression symptomatology change score




Figure 199: Remission (ITT)




Figure 200: Response (ITT)








Figure 201: Discontinuation due to side effects**Comparison 34. Augmenting with bupropion versus placebo****Figure 202: Remission (ITT)****Comparison 35. Augmenting with bupropion versus switching to bupropion****Figure 203: Remission (ITT)****Figure 204: Response (ITT)**

Figure 205: Discontinuation due to any reason





Figure 206: Discontinuation due to side effects



Comparison 36. Switching to mirtazapine versus continuing with antidepressant

Figure 207: Depression symptomatology endpoint




Figure 208: Depression symptomatology change score




Figure 209: Depression symptomatology at 4-month follow-up




Figure 210: Remission (ITT)




Figure 211: Remission (ITT) at 4-month follow-up




Figure 212: Response (ITT)




Figure 213: Discontinuation due to any reason




Figure 214: Discontinuation due to side effects






Figure 215: Quality of life physical component score (PCS) change score



Test for subgroup differences: Not applicable
AD: antidepressant


Figure 216: Quality of life mental component score (MCS) change score



Test for subgroup differences: Not applicable
AD: antidepressant

Comparison 37. Augmenting with mirtazapine versus continuing with antidepressant (+/- placebo)

Figure 217: Depression symptomatology endpoint



AD: antidepressant

Figure 218: Depression symptomatology change score




Figure 219: Depression symptomatology at 4-month follow-up




Figure 220: Remission (ITT)






Figure 221: Remission (ITT) at 4-month follow-up



Test for subgroup differences: Not applicable
 AD: antidepressant

Figure 222: Response (ITT)



AD: antidepressant

Figure 223: Discontinuation due to any reason




Figure 224: Discontinuation due to side effects




Figure 225: Quality of life endpoint




Figure 226: Quality of life physical component score (PCS) endpoint




Figure 227: Quality of life mental component score (MCS) endpoint





Figure 228: Global functioning endpoint



Comparison 38. Augmenting with mirtazapine versus switching to mirtazapine

Figure 229: Depression symptomatology endpoint




Figure 230: Depression symptomatology change score




Figure 231: Depression symptomatology at 4-month follow-up




Figure 232: Remission (ITT)




Figure 233: Remission (ITT) at 4-month follow-up




Figure 234: Response (ITT)









Figure 235: Discontinuation due to any reason**Figure 236: Discontinuation due to side effects****Comparison 39. Augmenting with trazodone versus continuing with antidepressant****Figure 237: Remission (ITT)**

Figure 238: Response (ITT)




Test for subgroup differences: Not applicable
AD: antidepressant

Figure 239: Quality of life physical component score (PCS) change score



Test for subgroup differences: Not applicable
AD: antidepressant


Figure 240: Quality of life mental component score (MCS) change score



Test for subgroup differences: Not applicable
AD: antidepressant


Comparison 40. Augmenting with anticonvulsant versus continuing with antidepressant (+/- placebo)

Figure 241: Depression symptomatology endpoint




AD: antidepressant


Figure 242: Depression symptomatology change score



AD: antidepressant

Figure 243: Remission (ITT)

Test for subgroup differences: Not applicable
 AD: antidepressant

Figure 244: Response (ITT)

AD: antidepressant

Figure 245: Discontinuation due to any reason




Figure 246: Discontinuation due to side effects




Figure 247: Quality of life physical component score (PCS) change score





Figure 248: Quality of life mental component score (MCS) change score



AD: antidepressant

Comparison 41. Augmenting with anticonvulsant versus lithium

Figure 249: Depression symptomatology endpoint




Figure 250: Depression symptomatology change score




Figure 251: Remission (ITT)




Figure 252: Response (ITT)






Figure 253: Discontinuation due to any reason

Test for subgroup differences: Not applicable

Figure 254: Discontinuation due to side effects

Test for subgroup differences: Not applicable


Comparison 42. Switching to antipsychotic versus continuing with antidepressant**Figure 255: Depression symptomatology change score****AD: antidepressant**

Figure 256: Remission (ITT)




Figure 257: Response (ITT)






Figure 258: Discontinuation due to any reason**Figure 259: Discontinuation due to side effects**

Figure 260: Quality of life physical component score (PCS) change score





Figure 261: Quality of life mental component score (MCS) change score



Comparison 43. Switching to combined antipsychotic + SSRI versus continuing with antidepressant

Figure 262: Depression symptomatology change score








Figure 263: Remission (ITT)**Figure 264: Response (ITT)**

Figure 265: Discontinuation due to any reason**Figure 266: Discontinuation due to side effects**



Comparison 44. Switching to combined antipsychotic + SSRI versus switch to SSRI-only**Figure 267: Depression symptomatology change score****Figure 268: Remission (ITT)**

Figure 269: Response (ITT)




Figure 270: Discontinuation due to any reason






Figure 271: Discontinuation due to side effects



AP: antipsychotic


Comparison 45. Augmenting with antipsychotic versus antidepressant-only or antidepressant + placebo

Figure 272: Depression symptomatology endpoint




AD: antidepressant; AP: antipsychotic

Figure 273: Depression symptomatology change score




AD: antidepressant; AP: antipsychotic

Figure 274: Remission (ITT)




AD: antidepressant; AP: antipsychotic

Figure 275: Response (ITT)



AD: antidepressant; AP: antipsychotic


Figure 276: Discontinuation due to any reason



<Insert Note here>


AD: antidepressant; AP: antipsychotic

Figure 277: Discontinuation due to side effects




AD: antidepressant; AP: antipsychotic

Figure 278: Quality of life endpoint




Test for subgroup differences: Not applicable
AD: antidepressant; AP: antipsychotic

Figure 279: Quality of life change score



AD: antidepressant; AP: antipsychotic

Figure 280: Quality of life physical component score (PCS) change score



AD: antidepressant; AP: antipsychotic

Figure 281: Quality of life mental component score (MCS) change score




Figure 282: Global functioning change score




Figure 283: Functional remission (≤6 total score on SDS and all SDS domain scores ≤2)






Figure 284: Functional impairment endpoint



Test for subgroup differences: Not applicable
AD: antidepressant; AP: antipsychotic

Figure 285: Functional impairment change score



AD: antidepressant; AP: antipsychotic

Comparison 46. Augmenting with antipsychotic versus bupropion

Figure 286: Depression symptomatology change score




Figure 287: Remission (ITT)




Figure 288: Response (ITT)






Figure 289: Discontinuation due to any reason**Figure 290: Discontinuation due to side effects**

Comparison 47. Augmenting with antipsychotic versus lithium

Figure 291: Remission (ITT)




Figure 292: Response (ITT)






Figure 293: Discontinuation due to any reason**Figure 294: Discontinuation due to side effects**

Comparison 48. Augmenting with antipsychotic versus switch to antipsychotic

Figure 295: Depression symptomatology change score




Figure 296: Remission (ITT)




Figure 297: Response (ITT)




Figure 298: Discontinuation due to any reason




Figure 299: Discontinuation due to side effects




Figure 300: Quality of life physical component score (PCS) change score





Figure 301: Quality of life mental component score (MCS) change score



Comparison 49. Augmenting with antipsychotic versus switch to bupropion

Figure 302: Remission (ITT)




Figure 303: Response (ITT)




Figure 304: Discontinuation due to any reason





Figure 305: Discontinuation due to side effects



Comparison 50. Augmenting with buspirone versus continuing with antidepressant (+/- placebo)

Figure 306: Remission (ITT)




Figure 307: Response (ITT)




Figure 308: Quality of life physical component score (PCS) change score





Figure 309: Quality of life mental component score (MCS) change score



Comparison 51. Augmenting with buspirone versus bupropion

Figure 310: Depression symptomatology endpoint




Figure 311: Depression symptomatology change score




Figure 312: Remission (ITT)




Figure 313: Response (ITT)





Figure 314: Discontinuation due to side effects



Comparison 52. Augmenting with methylphenidate versus placebo

Figure 315: Depression symptomatology change score




Figure 316: Remission (ITT)




Figure 317: Response (ITT)






Figure 318: Discontinuation due to any reason**Figure 319: Discontinuation due to side effects**

Comparison 53. Augmenting with lithium versus continuing with antidepressant (+/- placebo)


Figure 320: Depression symptomatology endpoint

Figure 321: Depression symptomatology change score




Figure 322: Remission (ITT)




Figure 323: Response (ITT)










Figure 324: Discontinuation due to any reason**Figure 325: Discontinuation due to side effects**

Comparison 54. Augmenting with lithium versus switch to antipsychotic**Figure 326: Remission (ITT)****Figure 327: Response (ITT)****Figure 328: Discontinuation due to any reason****Figure 329: Discontinuation due to side effects**

Comparison 55. Augmenting with lithium versus augmenting with a psychological intervention

Figure 330: Depression symptomatology endpoint




Figure 331: Depression symptomatology change score




Figure 332: Depression symptomatology at 1-month follow-up




Figure 333: Remission (ITT)




Figure 334: Discontinuation due to any reason





Figure 335: Discontinuation due to side effects



Comparison 56. Augmenting with lithium versus augmenting with TCA

Figure 336: Depression symptomatology endpoint




Figure 337: Depression symptomatology change score







Figure 338: Remission (ITT)**Figure 339: Discontinuation due to any reason****Figure 340: Discontinuation due to side effects**

Comparison 57. Augmenting with omega-3 fatty acids versus placebo

Figure 341: Depression symptomatology endpoint




Figure 342: Depression symptomatology change score




Figure 343: Remission (ITT)




Figure 344: Response (ITT)




Figure 345: Discontinuation due to any reason






Figure 346: Discontinuation due to side effects**Figure 347: Sleeping difficulties endpoint**

Comparison 58. Augmenting with thyroid hormone versus continuing with antidepressant (+/- placebo)


Figure 348: Depression symptomatology endpoint




Figure 349: Depression symptoms change score**Figure 350: Remission (ITT)****Figure 351: Response (ITT)**

Figure 352: Discontinuation due to any reason




Figure 353: Discontinuation due to side effects




Figure 354: Quality of life physical component score (PCS) change score





Figure 355: Quality of life mental component score (MCS) change score



Comparison 59. Augmenting with thyroid hormone versus augmenting with lithium

Figure 356: Depression symptomatology endpoint




Figure 357: Depression symptomatology change score




Figure 358: Remission (ITT)




Figure 359: Response (ITT)




Figure 360: Discontinuation due to any reason






Figure 361: Discontinuation due to side effects




Comparison 60. Switching to ECT versus switching to paroxetine


Figure 362: Depression symptomatology endpoint




AD: antidepressant

Figure 363: Depression symptomatology change score


AD: antidepressant

Figure 364: Response (ITT)

AD: antidepressant

Figure 365: Discontinuation due to any reason

AD: antidepressant

Figure 366: Discontinuation due to side effects

AD: antidepressant






Comparison 61. Augmenting with ECT versus continuing with antidepressant**Figure 367: Depression symptomatology endpoint****Figure 368: Depression symptomatology change score****Comparison 62. Augmenting with ECT versus augmenting with exercise****Figure 369: Depression symptomatology endpoint****Figure 370: Depression symptomatology change score**

Figure 371: Remission (ITT)



Comparison 63. Augmenting with ECT + exercise versus augmenting with exercise

Figure 372: Depression symptomatology endpoint




Figure 373: Depression symptomatology change score





Figure 374: Remission (ITT)



Comparison 64. Augmenting with exercise versus TAU

Figure 375: Depression symptomatology endpoint




Figure 376: Depression symptomatology change score




Figure 377: Remission (ITT)




Figure 378: Response (ITT)





Figure 379: Discontinuation due to any reason



Comparison 65. Augmenting with exercise versus attention-placebo

Figure 380: Depression symptomatology endpoint




Figure 381: Depression symptomatology change score









Figure 382: Remission (ITT)**Figure 383: Response (ITT)**

Figure 384: Discontinuation due to any reason**Figure 385: Global functioning change score****Figure 386: Sleeping difficulties endpoint**

Comparison 66. Augmenting with exercise + ECT versus augmenting with ECT

Figure 387: Depression symptomatology endpoint




Figure 388: Depression symptomatology change score





Figure 389: Remission (ITT)



Comparison 67. Augmenting with yoga versus continuing with antidepressant (+/- waitlist or attention-placebo)

Figure 390: Depression symptomatology change score




Figure 391: Remission (ITT)




Figure 392: Remission (ITT) at 3-month follow-up




Figure 393: Remission (ITT) at 6-month follow-up




Figure 394: Response (ITT)




Figure 395: Response (ITT) at 3-month follow-up




Figure 396: Response (ITT) at 6-month follow-up





Figure 397: Discontinuation due to any reason

AD: antidepressant